ProQR Therapeutics N.V. Ordinary Shares (PRQR) is a publicly traded Healthcare sector company. As of May 21, 2026, PRQR trades at $1.49 with a market cap of $159.10M and a P/E ratio of 0.00. PRQR moved +0.00% today. Year to date, PRQR is -29.90%; over the trailing twelve months it is -18.75%. Its 52-week range spans $1.07 to $4.62. Analyst consensus is strong buy with an average price target of $8.20. Rallies surfaces PRQR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in PRQR news today?
ProQR Unveils Preclinical AX-0422, AX-2402, AX-2911 Data and AX-0810 Clinical Preview: ProQR will present data on AX-0422 in Hurler syndrome, AX-2402 in Rett syndrome and AX-2911 for hepatic steatosis at TIDES USA, ASGCT, RNA Society and EASL conferences in May. Its lead program AX-0810 is advancing toward initial clinical data in healthy volunteers later this quarter.
ProQR Unveils Preclinical AX-0422, AX-2402, AX-2911 Data and AX-0810 Clinical Preview: ProQR will present data on AX-0422 in Hurler syndrome, AX-2402 in Rett syndrome and AX-2911 for hepatic steatosis at TIDES USA, ASGCT, RNA Society and EASL conferences in May. Its lead program AX-0810 is advancing toward initial clinical data in healthy volunteers later this quarter.
Does Rallies summarize PRQR news?
Yes. Rallies summarizes PRQR news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is PRQR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for PRQR. It does not provide personalized investment advice.
